The accompanying notes are an integral part of these unaudited interim financial statements.
The accompanying notes are an integral part of these unaudited interim financial statements.
The accompanying notes are an integral part of these unaudited interim financial statements.
The accompanying notes are an integral part of these unaudited interim financial statements.
NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS
NOVEMBER 30, 2018
NOTE 1 – ORGANIZATION, DESCRIPTION OF BUSINESS AND GOING CONCERN
Airborne Wireless Network (the “
Company
”) is a Nevada corporation incorporated on January 5, 2011 under the name Ample-Tee. Effective on May 19, 2016, the Company’s corporate name was changed to Airborne Wireless Network. It is based in Simi Valley, California, USA. The Company’s fiscal year end is August 31.
We are an early stage company with the principal business strategy of developing, marketing and licensing a fully meshed, high-speed broadband airborne wireless network by linking commercial aircraft in flight. We call this network the “Infinitus Super Highway
SM
” (“
Infinitus
”).
Amended and Restated Articles of Incorporation
On June 28, 2018, the stockholders of the Company approved an amendment (the “
Amendment
”) to the Company’s Amended and Restated Articles of Incorporation (as amended to date, the “
Articles
”) that increased the number of authorized shares of stock and granted the Company the right to effect up to five reverse stock splits of all of the Company’s issued and outstanding common stock. The number of shares of stock authorized under the Articles prior to the Amendment was 360,000,000, of which 350,000,000 were designated as common stock and 10,000,000 were designated as preferred stock. After giving effect to the Amendment, the number of authorized shares of all classes of stock the Company has authority to issue is 5,000,010,000,000, of which 5,000,000,000,000 are be designated as common stock and 10,000,000 are designated as preferred stock. Under the Amendment, the board of directors of the Company can effect up to five separate reverse splits of the Common Stock, each to be in a ratio of up to thirty thousand (30,000) to one (1), with any fractional shares to be rounded up to the next whole share, or paid in cash. Effective August 24, 2018, the Company effected a 30,000-for-one reverse stock split. All shares of common stock, the number of shares underlying options, warrants and other convertible securities and the per-share exercise price of such options, warrants and convertible securities disclosed in the financial statements retroactively reflect this reverse stock split.
Going concern
The Company’s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“
U.S. GAAP
”), which contemplates the Company’s continuation as a going concern. The Company incurred operating losses of $9,810,949 during the period ended November 30, 2018 and has an accumulated deficit of $123,623,002 as of November 30, 2018.
There are no assurances that the Company will be able to either (1) achieve a level of revenues adequate to generate sufficient cash flow from operations; or (2) obtain additional financing through either private placements, public offerings and/or bank financing necessary to support its working capital requirements. To the extent that funds generated from operations and any private placements, public offerings and/or bank financing are insufficient, the Company will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on terms acceptable to the Company. If adequate working capital is not available to the Company, it may be required to curtail or cease its operations.
Due to uncertainties related to these matters, there exists a substantial doubt about the ability of the Company to continue as a going concern. The accompanying unaudited interim financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation of Interim Financial Statements
The accompanying unaudited interim financial statements have been prepared in accordance with U.S. GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Regulation S-X. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended November 30, 2018 are not necessarily indicative of the results that may be expected for the year ending August 31, 2019. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for fiscal year 2018 have been omitted. This report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended August 31, 2018 included in the Company’s Form 10-K as filed with the Securities and Exchange Commission on November 14, 2018.
Use of Estimates and Assumptions
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Fair Value of Financial Instruments
The Company’s financial instruments consist primarily of cash, prepaid expense, deferred financing cost, accounts payable and accrued liabilities, accrued expenses, convertible notes and notes payable. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.
The Company adopted ASC Topic 820,
Fair Value Measurements
(“
ASC Topic 820
”), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The standard provides a consistent definition of fair value which focuses on an exit price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The standard also prioritizes, within the measurement of fair value, the use of market-based information over entity specific information and establishes a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.
The three-level hierarchy for fair value measurements is defined as follows:
Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets; liabilities in active markets;
Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly, including inputs in markets that are not considered to be active; or directly or indirectly including inputs in markets that are not considered to be active;
Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement
The following table summarizes fair value measurements by level at November 30, 2018, and August 31, 2018, measured at fair value on a recurring basis:
November 30, 2018
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
|
Total
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivative Liabilities
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
3,105,129
|
|
|
$
|
3,105,129
|
|
August 31, 2018
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
|
Total
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivative Liabilities
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
4,494,698
|
|
|
$
|
4,494,698
|
|
Research and Development Expenses
We follow ASC 730-10,
”Research and Development,”
and expense research and development costs when incurred. Accordingly, third-party research and development costs, including designing, prototyping and testing of product, are expensed when the contracted work has been performed or milestone results have been achieved. Indirect costs are allocated based on percentage usage related to the research and development. Research and development costs of $55,141 and $285,889 were incurred for the three months ended November 30, 2018 and 2017, respectively.
Stock-Based Compensation
ASC 718,
”Compensation - Stock Compensation,”
prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).
The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50,
”Equity - Based Payments to Non-Employees.”
Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.
Stock-based compensation incurred for the three months ended November 30, 2018 and 2017, respectively, are summarized as follows:
|
|
November 30,
|
|
|
|
2018
|
|
|
2017
|
|
|
|
|
|
|
|
|
Stock options issued to employees, strategic service provider and consultants
|
|
$
|
4,292,178
|
|
|
$
|
5,545,200
|
|
Stock warrants issued to investors and consultants
|
|
|
-
|
|
|
|
186,968
|
|
Common stock issued to strategic service providers and consultants
|
|
|
18,150
|
|
|
|
230,357
|
|
Total
|
|
$
|
4,310,328
|
|
|
$
|
5,962,525
|
|
Recently Issued Accounting Pronouncements
In August 2018, the Financial Accounting Standards Board issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. The ASU modifies the disclosure requirements in Topic 820, Fair Value Measurement, by removing certain disclosure requirements related to the fair value hierarchy, modifying existing disclosure requirements related to measurement uncertainty and adding new disclosure requirements, such as disclosing the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and disclosing the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This ASU is effective for public companies for annual reporting periods and interim periods within those annual periods beginning after December 15, 2019. The Company is currently evaluating the effect, if any, that the ASU will have on its financial statements.
Management has considered all other recent accounting pronouncements issued. The Company’s management believes that these recent pronouncements will not have a material effect on the Company’s unaudited interim financial statements.
NOTE 3 – PREPAID EXPENSES
Prepaid expenses relate to prepayment made for future services in advance and will be expensed over time as the benefit of the services is received in the future, expected within one year.
Prepaid expenses consisted of the following at November 30, 2018 and August 31, 2018:
|
|
November 30,
|
|
|
August 31,
|
|
|
|
2018
|
|
|
2018
|
|
Legal and regulatory fees
|
|
$
|
108,258
|
|
|
$
|
255,500
|
|
Marketing and branding
|
|
|
4,500
|
|
|
|
712,900
|
|
Rent expense
|
|
|
9,020
|
|
|
|
22,550
|
|
Professional fees
|
|
|
7,175
|
|
|
|
28,700
|
|
|
|
$
|
128,953
|
|
|
$
|
1,019,650
|
|
NOTE 4 – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
Accounts payable and accrued liabilities consisted of the following at November 30, 2018 and August 31, 2018:
|
|
November 30,
|
|
|
August 31,
|
|
|
|
2018
|
|
|
2018
|
|
Trade Payables
|
|
$
|
8,302,628
|
|
|
$
|
4,796,784
|
|
Credit Card Payable
|
|
|
38,745
|
|
|
|
37,675
|
|
Other Payable
|
|
|
69,960
|
|
|
|
74,960
|
|
Total
|
|
$
|
8,411,333
|
|
|
$
|
4,909,419
|
|
NOTE 5 – EQUITY
Authorized Stock
The Company is authorized to issue an aggregate of 5,000,000,000,000 common shares and 10,000,000 shares of preferred stock, each with a par value of $0.001 per share. Each common share entitles the holder to one vote on any matter on which action of the stockholders of the corporation is sought.
Series A Convertible Preferred stock
The Company is authorized to issue 1,000,000 shares of Series A Convertible Preferred Stock at a par value of $0.001 and a stated value equal to $1,150 per share.
|
·
|
The Series A Convertible Preferred Stock ranks senior to our common stock and other classes of capital stock with respect to dividend and redemption.
|
|
|
|
|
·
|
Holders of the Series A Convertible Preferred Stock will only be entitled to receive any dividends on the Series A Preferred Stock when, as and if the board of directors declares such dividends.
|
|
|
|
|
·
|
The Series A Convertible Preferred Stock is convertible into shares of common stock by dividing the stated value per share ($1,150) by the lesser of $0.71 per share or 82.5% of the lowest volume weighted average price for our common stock as reported at the close of trading on the market reporting trade prices for the common stock during the five trading days ending on and including the day the notice of conversion is delivered.
|
|
|
|
|
·
|
A holder of Series A Convertible Preferred Stock has the same voting rights as a holder of common stock on a fully converted basis not to exceed the beneficial ownership limitation.
|
On May 29, 2018, the Company issued 8,000 units for aggregate net proceeds of $6.7 million, after deducting underwriting discounts and other expenses of the offering. Each unit consisted of one share of Series A Preferred Stock, one Series 1 warrant to purchase one share of Series A Preferred Stock, one Series 2 warrant to purchase one share of Series A Preferred Stock and one Series 3 warrant to purchase one share of Series A Preferred Stock (“
Series 1, 2 and 3 warrants
”). The Company also issued to the underwriter of the offering a warrant to purchase 640 units.
The Company determined that the Series A Convertible Preferred Stock qualifies for derivative accounting which led to no explicit limit to the number of shares to be delivered upon future settlement of the conversion options (See Note 8).
During the three months ended November 30, 2018, 749 shares of Series A Convertible Preferred Stock were converted into 2,632,629,380 shares of common stock.
As of November 30, 2018, and August 31, 2018, 1,099 and 1,048 shares of Series A Convertible Preferred Stock were issued and outstanding, respectively.
Warrants Exercisable into Preferred A Stock
Each warrant is immediately exercisable into one share of Series A Convertible Preferred Stock at a price of $1,000 per share. The Series 1 Warrants will expire on the 90-day anniversary of the issuance date. The Series 2 Warrants will expire on the six-month anniversary of the issuance date. The Series 3 Warrants will expire on the 12-month anniversary of the issuance date. During the three months ended November 30, 2018, the Company amended the expiry date of Series 1, 2 and 3 warrant to May 29, 2019.
The below table summarizes warrant activity during the three months ended November 30, 2018 and the year ended August 31, 2018:
|
|
Number of warrants
|
|
|
Weighted- Average Exercise Price
|
|
|
|
Series 1
|
|
|
Series 2
|
|
|
Series 3
|
|
|
Series 1
|
|
|
Series 2
|
|
|
Series 3
|
|
Balances as of August 31, 2018
|
|
|
7,500
|
|
|
|
7,900
|
|
|
|
8,000
|
|
|
$
|
1,000
|
|
|
$
|
1,000
|
|
|
$
|
1,000
|
|
Granted
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Exercised
|
|
|
-
|
|
|
|
(200
|
)
|
|
|
(600
|
)
|
|
|
1,000
|
|
|
|
1,000
|
|
|
|
1,000
|
|
Forfeited
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Balances as of November 30, 2018
|
|
|
7,500
|
|
|
|
7,700
|
|
|
|
7,400
|
|
|
$
|
1,000
|
|
|
$
|
1,000
|
|
|
$
|
1,000
|
|
The following table summarizes information relating to outstanding and exercisable warrants as of November 30, 2018:
|
|
Warrants Outstanding
|
|
|
Warrants Exercisable
|
|
|
|
|
|
|
Weighted Average
|
|
|
Weighted
|
|
|
|
|
|
Weighted
|
|
|
|
Number
|
|
|
Remaining
|
|
|
Average
|
|
|
Number
|
|
|
Average
|
|
|
|
of Shares
|
|
|
life (in Months)
|
|
|
Exercise Price
|
|
|
of Shares
|
|
|
Exercise Price
|
|
Series 1
|
|
|
7,500
|
|
|
|
5.92
|
|
|
$
|
1,000
|
|
|
|
7,500
|
|
|
$
|
1,000
|
|
Series 2
|
|
|
7,700
|
|
|
|
5.92
|
|
|
$
|
1,000
|
|
|
|
7,700
|
|
|
$
|
1,000
|
|
Series 3
|
|
|
7,400
|
|
|
|
5.92
|
|
|
$
|
1,000
|
|
|
|
7,400
|
|
|
$
|
1,000
|
|
During the three months ended November 30, 2018, 200 Series 2 warrants were exercised into 200 shares of Series A Convertible Preferred Stock and 600 Series 3 warrants were exercised into 600 shares of Series A Convertible Preferred Stock.
Common stock
Issuances
During the three months ended November 30, 2018, the Company issued 2,936,416,936 shares of common stock, as follows:
|
·
|
46,242,792 shares of common stock to strategic service providers, for services valued at $18,150.
|
|
|
|
|
·
|
2,632,629,380 shares of common stock issued for the conversion of 749 shares of Series A Convertible Preferred Stock.
|
|
|
|
|
·
|
257,544,764 shares of common stock issued upon the conversion of convertible notes in aggregate principal amount of $34,075 and accrued interest of $13,112.
|
As at November 30, 2018 and August 31, 2018, the Company had 2,937,101,278 and 684,342 shares of common stock issued and outstanding, respectively.
Warrants Exercisable to Common Shares
The below table summarizes the activity of warrants exercisable for common shares during the three months ended November 30, 2018 and the year ended August 31, 2018:
|
|
Number
of Shares
|
|
|
Weighted-
Average
Exercise Price
|
|
Balances as of August 31, 2017
|
|
|
119
|
|
|
$
|
48,900
|
|
Granted
|
|
|
3,513
|
|
|
|
4,505
|
|
Exercised
|
|
|
(92
|
)
|
|
|
40,823
|
|
Forfeited
|
|
|
(231
|
)
|
|
|
46,862
|
|
Balances as of August 31, 2018
|
|
|
3,309
|
|
|
$
|
1,196
|
|
Granted
|
|
|
3
|
|
|
|
57,000
|
|
Exercised
|
|
|
-
|
|
|
|
-
|
|
Forfeited
|
|
|
-
|
|
|
|
-
|
|
Balances as of November 30, 2018
|
|
|
3,312
|
|
|
$
|
2,196
|
|
The fair value of each warrant on the date of grant is estimated using the Black-Scholes option valuation model. The following weighted-average assumptions were used for options granted during the year ended August 31, 2018:
|
|
Year Ended
|
|
|
|
August 31,
|
|
|
|
2018
|
|
Exercise price
|
|
$10.2 - $97,500
|
|
Expected term
|
|
1.49 - 5 years
|
|
Expected average volatility
|
|
124%-354%
|
|
Expected dividend yield
|
|
-
|
|
Risk-free interest rate
|
|
0.98% - 2.83%
|
|
The following table summarizes information relating to outstanding and exercisable warrants as of November 30, 2018:
Warrants Outstanding
|
|
|
Warrants Exercisable
|
|
|
|
|
Weighted Average
|
|
|
Weighted
|
|
|
|
|
|
Weighted
|
|
Number
|
|
|
Remaining Contractual
|
|
|
Average
|
|
|
Number
|
|
|
Average
|
|
of Shares
|
|
|
life (in years)
|
|
|
Exercise Price
|
|
|
of Shares
|
|
|
Exercise Price
|
|
|
3,312
|
|
|
|
2.64
|
|
|
$
|
2,196
|
|
|
|
3,312
|
|
|
|
2,196
|
|
Aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company’s stock exceeded the exercise price of the warrants at November 30, 2018 for those warrants for which the quoted market price was in excess of the exercise price (“in-the-money” warrants). As of November 30, 2018, the aggregate intrinsic value of warrants outstanding was approximately $0 based on the closing market price of $0.0001 on November 30, 2018.
The Company determined that the warrants qualify for derivative accounting as a result of the related issuances of convertible notes, which led to no explicit limit to the number of shares to be delivered upon future settlement of the conversion options.
NOTE 6 – STOCK COMPENSATION PLANS
In the ordinary course of business, the Company may issue stock options to employees, officers and directors from time to time. Fair values of the stock option awards are based on the associated value of the services rendered, where reasonably determinable.
Equity Compensation not approved by security holders
During the three months ended November 30, 2018 and the year ended August 31, 2018, options to purchase 0 and 339 shares of our common stock, respectively, had been granted to our employees, officers and directors under equity compensation not approved by security holders.
Options issued had the following terms:
|
|
Year Ended
|
|
|
August 31,
|
|
|
2018
|
Exercise price
|
|
$15,000 - $97,500
|
Time to vest
|
|
On issuance – 4 years
|
Expiration after vesting
|
|
5 years
|
2017 Equity Incentive Plan
On July 30, 2017, the Board of Directors of the Company approved, and on July 31, 2017 the stockholders of the Company approved, the Airborne Wireless Network 2017 Stock Option Plan (the “
2017 Plan
”). The 2017 Plan permits the Company to issue up to 334 shares of common stock upon exercise of options granted to selected employees, officers, directors, consultants and advisers. The options may be either “incentive stock options” (as such term is defined in the Internal Revenue Code of 1986) or options that are not intended to qualify as “incentive stock options” (these are referred to as “non-qualified options”). Incentive stock options may be granted only to employees. The 2017 Plan is administered by the Board or, at the discretion of the Board, a Board committee. The administrator determines who will receive options and the terms of the options, including the exercise price, expiration date, vesting and the number of shares. The exercise price of each stock option may not be less than the fair market value of the Common Stock on the date of grant, although the exercise price of any incentive stock option granted to a 10% stockholder may not be less than 110% of the fair market value on the grant date. Options may be exercisable (“vest”) immediately or in increments based on time and/or performance criteria as determined by the administrator. The term of any option may not exceed 10 years (five years for any incentive stock option granted to a 10% stockholder), and unless otherwise determined by the administrator, each option must terminate no later than three months after the termination of the optionee’s employment (one year in the event of death or disability). Subject to a few minor exceptions, options may not be transferred other than by will or by the laws of descent and distribution. The 2017 Plan will expire on December 31, 2026.
On December 30, 2017, the Company granted options to directors (see below) to purchase an aggregate of 14 shares of our common stock at a price of $59,400 per share vesting immediately on December 31, 2017. The options expire December 29, 2022, unless such director ceases his or her service as a director prior the exercise or expiration of the option.
As of November 30, 2018, there were 320 shares available for future grant under the 2017 Plan.
Stock Options
During the three months ended November 30, 2018, the Company did not grant options and during the year ended August 31, 2018, the Company granted options with an aggregate fair value of $19,412,264, which are being amortized into compensation expense over the vesting period of the options as the services are being provided.
The following is a summary of stock option activity during the three months ended November 30, 2018 and the year ended August 31, 2018:
|
|
Options Outstanding
|
|
|
|
Number
of Shares
|
|
|
Weighted-
Average
Exercise Price
|
|
|
Fair Value
on Grant Date
|
|
|
Intrinsic
Value
|
|
Balances as of August 31, 2017
|
|
|
946
|
|
|
|
98,700
|
|
|
|
35,864,990
|
|
|
|
-
|
|
Granted
|
|
|
339
|
|
|
|
66,000
|
|
|
|
19,412,264
|
|
|
|
-
|
|
Exercised
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Forfeited
|
|
|
(2
|
)
|
|
|
37,200
|
|
|
|
(67,894
|
)
|
|
|
-
|
|
Balances as of August 31, 2018
|
|
|
1,283
|
|
|
$
|
58,500
|
|
|
$
|
55,209,360
|
|
|
$
|
-
|
|
Granted
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Exercised
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Forfeited
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Balances as of November 30, 2018
|
|
|
1,283
|
|
|
$
|
58,504
|
|
|
$
|
55,209,360
|
|
|
$
|
-
|
|
The following table summarizes information relating to exercisable stock options as of November 30, 2018:
Options Exercisable
|
Number of Shares
|
|
|
Weighted Average Exercise Price
|
|
|
660
|
|
|
$
|
45,979
|
|
Aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company’s stock exceeded the exercise price of the stock options exercisable at November 30, 2018. As of November 30, 2018, the aggregate intrinsic value of stock options outstanding was $0 based on the closing market price of $0.0001 on November 30, 2018.
Weighted-average grant-date fair value for non-vested stock options as of November 30, 2018 and August 31, 2018 were listed as follows:
|
|
Shares
|
|
|
Weighted-
Average Grant
Date Fair Value
Per Share
|
|
Unvested, August 31, 2017
|
|
|
809
|
|
|
$
|
38,100
|
|
Granted
|
|
|
339
|
|
|
|
57,300
|
|
Vested
|
|
|
(473
|
)
|
|
|
43,800
|
|
Forfeited
|
|
|
-
|
|
|
|
-
|
|
Unvested, August 31, 2018
|
|
|
675
|
|
|
$
|
43,800
|
|
Granted
|
|
|
-
|
|
|
|
-
|
|
Vested
|
|
|
(52
|
)
|
|
|
37,500
|
|
Forfeited
|
|
|
-
|
|
|
|
-
|
|
Unvested, November 30, 2018
|
|
|
623
|
|
|
$
|
43,800
|
|
The fair value of each option on the date of grant is estimated using the Black-Scholes option valuation model. The following weighted-average assumptions were used for options granted during the year ended August 31, 2018 and 2017:
|
|
Year Ended
|
|
|
|
August 31,
|
|
|
|
2018
|
|
|
2017
|
|
Expected term
|
|
3.59 - 5.98 years
|
|
|
4.59 - 6.43 years
|
|
Expected average volatility
|
|
175% - 176%
|
|
|
179% - 183%
|
|
Expected dividend yield
|
|
-
|
|
|
-
|
|
Risk-free interest rate
|
|
2.20% - 2.35%
|
|
|
1.17% - 2.25%
|
|
The total fair values of stock options that vested during the period ended November 30, 2018 and year ended August 31, 2018 were $2,510,847 and $18,112,430, respectively.
As of November 30, 2018, there was $7,831,411 of total unrecognized compensation cost related to non-vested stock options granted. The Company expects to recognize that cost over a remaining weighted average vesting period of 0.55 years as of November 30, 2018.
NOTE 7 – CONVERTIBLE NOTES
The Company had the following principal balances under its convertible notes outstanding as of November 30, 2018 and August 31, 2018:
|
|
November 30,
|
|
|
August 31,
|
|
|
|
2018
|
|
|
2018
|
|
Convertible Notes - originated in October 2017
|
|
$
|
162,700
|
|
|
$
|
164,190
|
|
Convertible Notes - originated in December 2017
|
|
|
109,725
|
|
|
|
109,725
|
|
Convertible Notes - originated in January 2018
|
|
|
1,915
|
|
|
|
24,500
|
|
Convertible Notes - originated in March 2018
|
|
|
145,833
|
|
|
|
145,833
|
|
Convertible Notes - originated in April 2018
|
|
|
1,190,000
|
|
|
|
1,250,000
|
|
Convertible Notes - originated in May 2018
|
|
|
145,832
|
|
|
|
145,833
|
|
|
|
|
1,756,005
|
|
|
|
1,840,081
|
|
Less debt discount and debt issuance cost
|
|
|
(349,422
|
)
|
|
|
(863,852
|
)
|
|
|
|
1,406,583
|
|
|
|
976,229
|
|
Less current portion of convertible notes payable
|
|
|
(1,406,583
|
)
|
|
|
(976,229
|
)
|
Long-term convertible notes payable
|
|
$
|
-
|
|
|
$
|
-
|
|
The Company recognized amortization expense related to the debt discount and deferred financing fees of $514,429 and $953,451 for the three months ended November 30, 2018 and 2017, respectively, which is included in interest expense in the statements of operations.
For the three months ended November 30, 2018 and 2017, the interest expense on convertible notes was $49,874 and $27,153, respectively. As of November 30, 2018 and August 31, 2018, the accrued interest payable was $103,919 and $67,157, respectively.
Conversion
During the three months ended November 30, 2018, holders of certain of the convertible notes converted these notes with principal amounts of $34,075 and accrued interest of $13,112 into 257,544,764 shares of common stock. The corresponding derivative liability at the date of conversion of $122,122 was credited to additional paid in capital.
Convertible Notes – Issued during the year ended August 31, 2018
During the year ended August 31, 2018, the Company issued a total principal amount of $6,618,099 convertible notes for cash proceeds of $5,662,750, after deducting an original issuance discount of $629,099 and financing fees of $326,250. The convertible notes were also provided with a total of 53 common shares and warrants to purchase up to 25 shares of common stock at exercise prices ranging from $52,500 to $60,000 per share. The terms of convertible notes are summarized as follows:
|
·
|
Term ranging from six months to one year;
|
|
|
|
|
·
|
Annual interest rates ranging from 0% to 12%;
|
|
|
|
|
·
|
Convertible at the option of the holders either at issuance or 180 days from issuance; and
|
|
|
|
|
·
|
Conversion prices are typically based on 55% or 70% of the lowest trading prices of the Company’s shares during 20-25 days prior to the conversion.
|
NOTE 8 – DERIVATIVE LIABILITIES
The Company analyzed the conversion option for derivative accounting consideration under ASC 815, “
Derivatives and Hedging,”
and determined that the convertible notes should be classified as a liability since the conversion option becomes effective at issuance resulting in there being no explicit limit to the number of shares to be delivered upon settlement of the above conversion options. The Company accounts for warrants and Series A Convertible Preferred Stock as a derivative liability due to there being no explicit limit to the number of shares to be delivered upon settlement of all conversion options.
The Company determined our derivative liabilities to be a Level 3 fair value measurement and used the Black-Scholes pricing model to calculate the fair value as of November 30, 2018. The Black-Scholes model requires six basic data inputs: the exercise or strike price, time to expiration, the risk-free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each convertible note and warrant is estimated using the Black-Scholes valuation model. The following weighted-average assumptions were used in November 30, 2018 and August 31, 2018:
|
|
Three months ended
|
|
Year Ended
|
|
|
November 30,
|
|
August 31,
|
|
|
2018
|
|
2018
|
Expected term
|
|
0.11 - 0.50 years
|
|
0.10 - 5.00 years
|
Expected average volatility
|
|
283% - 580%
|
|
49% - 350%
|
Expected dividend yield
|
|
-
|
|
-
|
Risk-free interest rate
|
|
2.31%-2.52%
|
|
0.98% - 2.83%
|
The following table summarizes the derivative liabilities included in the balance sheet at November 30, 2018:
Fair Value Measurements Using Significant Observable Inputs (Level 3)
|
|
Balance - August 31, 2018
|
|
$
|
4,494,698
|
|
Addition of new derivative liabilities recognized upon issuance of convertible preferred stock
|
|
|
1,106,610
|
|
Derivative liabilities settled upon conversion of convertible notes
|
|
|
(122,122
|
)
|
Derivative liabilities settled upon conversion of convertible preferred stock
|
|
|
(1,032,555
|
)
|
Loss on change in fair value of the derivative liabilities
|
|
|
(1,341,502
|
)
|
Balance - November 30, 2018
|
|
$
|
3,105,129
|
|
The following table summarizes the (gain) loss on derivative liability included in the income statement for the three months ended November 30, 2018 and 2017, respectively.
|
|
Three months ended
|
|
|
|
November 30,
|
|
|
|
2018
|
|
|
2017
|
|
Addition of new derivative liabilities recognized as day one loss on derivatives from convertible notes
|
|
$
|
-
|
|
|
$
|
140,251
|
|
Addition of new derivative liabilities recognized upon issuance of convertible preferred stock
|
|
|
1,106,610
|
|
|
|
-
|
|
Addition of new derivative liabilities recognized as day one loss on derivatives from warrants
|
|
|
-
|
|
|
|
859,488
|
|
(Gain) loss on change in fair value of the derivative liabilities
|
|
|
(1,341,502
|
)
|
|
|
(464,671
|
)
|
|
|
$
|
(234,892
|
)
|
|
$
|
535,068
|
|
NOTE 9 – COMMITMENTS AND CONTINGENCIES
Anti-Dilution Agreements
Pursuant to our agreement with Jet Midwest Group, LLC entered into in October 2016, in consideration of the services to be provided by Jet Midwest Group, LLC, we issued to Jet Midwest Group, LLC 1,250,000 shares of common stock representing 1.6% of our common stock outstanding at that date. The agreement with Jet Midwest Group, LLC provides full ratchet anti-dilution protection to Jet Midwest Group, LLC. As a result, each time we issue additional shares of common stock or shares of another class or series of capital stock, we will issue to Jet Midwest Group, LLC without further consideration additional shares of our common stock or other class or series of capital stock so that Jet Midwest Group, LLC will continue to own 1.6% of the outstanding shares of common stock and each other class or series of capital stock. Through November 30, 2018, we had issued 49 shares of common stock to Jet Midwest Group, LLC and were obligated to issue an additional 46,253,639 shares of common stock. After entering into the agreement with us, Jet Midwest Group, LLC sought protection from creditors under the bankruptcy code, which proceedings were subsequently dismissed. One of Jet Midwest Group, LLC’s creditors has claimed that shares of our common stock to be issued under the anti-dilution right should be issued to it instead of Jet Midwest Group, LLC. In light of this dispute and ongoing litigation between Jet Midwest Group, LLC and its creditors, the Company is evaluating its obligation to continue issuing shares to Jet Midwest Group, LLC.
Consulting agreement
On July 31, 2017, the Company engaged Brighton Capital, Ltd. (“
Brighton
”) for a three (3) year term to render strategic advisory services. Pursuant to our agreement with Brighton, in consideration of the services to be provided by Brighton, we are to issue 14 shares of common stock and 34 warrants over a three-year term. We issued 2 shares of common stock and 4 warrants upon execution of this agreement, and are to issue 1 shares of common stock and 1 warrant per month for thirty-six (36) months, with the first issuance beginning August 1, 2017. Through November 30, 2018, we had issued 18 shares of common stock and 20 warrants to purchase common stock to Brighton. The warrants, as issued, shall immediately vest and have a term of five (5) years with an exercise price of $57,000 per share. The warrants have a cashless exercise feature that can be utilized if the shares underlying the warrants cannot be resold under an effective registration statement filed with the Securities and Exchange Commission by March 1, 2018.
Other
On August 3, 2016, we acquired from Apcentive, Inc. (“Apcentive”) all of Apcentive’s right, title and interest in and to U.S. Patent No. 6,285,878 B1 and all related supporting materials, continuations, amendments, updates and contemplated updates and amendments and the trademark “Infinitus Super Highway
SM
.” In consideration for the patent and the trademark, we issued a number of shares of our common stock to Apcentive and agreed to pay Apcentive a future royalty equal to 1.5% of the net cash we receive from the promotion, marketing, sale, licensing, distribution and other exploitation of the patent. We are further required to issue an additional 20 million shares of common stock to Apcentive if we do not spend, on matters relating to the patent and trademark, a cumulative total of $8 million on or before August 3, 2019. The purchase agreement requires that we spend at least $1 million on or before August 3, 2017 (which goal has been met), a total of at least $2 million on or before August 3, 2018 (which goal has been met) and a total of at least $5 million on or before August 3, 2019. As of November 30, 2018, the Company has not made a contingency for these events, but has expensed these costs, as incurred, which have exceeded the commitment.
From time to time, the Company is involved in routine litigation that arises in the ordinary course of business. There are no pending significant legal proceedings to which the Company is a party for which management believes the ultimate outcome would have a material adverse effect on the Company'’s financial position.
Lease Commitment
In June 2016, we signed a lease agreement that commenced on July 1, 2016 for our corporate office headquarters with approximately 1,500 square feet, at 4115 Guardian Street, Simi Valley, California 93063. The lease expired on August 31, 2017 and our monthly rent was $1,750 (plus HVAC charges), payable in equal monthly installments. In August 2017, the lease was extended by two years commencing September 1, 2017 at $1,803 per month (plus HVAC charges) for the first year and $1,857 per month (plus HVAC charges) for the second year.
On February 1, 2018, the Company signed an operating lease for a residence to be used by our Chief Executive Officer, located in Moorpark, California. The lease term commenced on February 1, 2018 and expires on January 31, 2019. Our monthly rent is $4,510, payable in equal monthly installments. On February 1, 2018, the Company prepaid the $54,120, for the full term of the lease. As at November 30, 2018, we recognized $9,020 as a prepaid expense.
Total net rent expense related to our operating leases for the three months ended November 30, 2018 and 2017, was $5,570 and $5,355 respectively.
Future minimum payments under the non-cancelable portion of our operating leases as of August 31, 2018 are as follows:
Year ended August 31,
|
|
|
|
2019
|
|
|
22,284
|
|
Thereafter
|
|
|
-
|
|
Total
|
|
$
|
22,284
|
|
NOTE 10 – SUBSEQUENT EVENTS
Subsequent to November 30, 2018 and through the date that these financials were made available, the Company had the following subsequent events:
On December 6, 2018, the Company issued 195,151,516 shares of common stock for the conversion of 14 shares of preferred stock.
On December 17, 2018, the Company and Sabby Volatility Warrant Master Fund, Ltd. (“
Sabby
”) entered into that certain Exercise Agreement pursuant to which Sabby, which holds certain shares of the Company’s Series A Convertible Preferred Stock (the “
Preferred Stock
”) and warrants to purchase shares of the Preferred Stock, agreed to exercise a minimum of $90,000 of its warrants on or immediately following December 17, 2018. Under the terms of the Sabby Exercise Agreement, the Company also committed to not issue, sell or offer any securities without the consent of Sabby until 11:59 p.m. on January 9, 2019. On December 18, 2018, we received gross proceeds of $90,000 from the exercise of 90 warrants into 90 shares of Preferred Stock.
On December 28, 2018, the Company issued 195,151,516 shares of common stock for the conversion of 14 shares of preferred stock.